Jacobs Levy Equity Management’s UroGen Pharma URGN Stock Holding History

Jacobs Levy Equity Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$585K	Sell	32,509 -6,874	-17%	-$138K	﹤0.01%	795
2025 Q4	$922K	Buy	39,383 +18,007	+84%	+$391K	﹤0.01%	694
2025 Q3	$426K	Buy	+21,376	New	+$384K	﹤0.01%	840
2021 Q4	–	Sell	-21,530	Closed	-$362K	–	1078
2021 Q3	$362K	Buy	21,530 +7,982	+59%	+$127K	﹤0.01%	911
2021 Q2	$207K	Buy	+13,548	New	+$245K	﹤0.01%	983

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Jacobs Levy Equity Management's URGN Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its UroGen Pharma (URGN) stake by 17% in Q1 2026, selling an estimated $138K and leaving 32,509 shares worth $585K. The position accounts for ﹤0.01% of the portfolio, ranked #795.

Jacobs Levy Equity Management first reported a position in URGN in Q2 2021 and has held it in 5 quarters since. The position peaked at $922K in Q4 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Jacobs Levy Equity Management held 32,509 shares of UroGen Pharma worth $585K as of Q1 2026.
Jacobs Levy Equity Management sold 6,874 UroGen Pharma shares in Q1 2026, an estimated $138K.
UroGen Pharma made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #795 holding.
Jacobs Levy Equity Management first reported a position in UroGen Pharma in Q2 2021 and has held it in 5 quarters since.
Jacobs Levy Equity Management's UroGen Pharma position peaked at $922K in Q4 2025.
172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.